Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988205 · ClinicalTrials.gov registry record · Phase 4
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03988205 is a Phase 4 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 3 participants.
The verdict
NCT03988205, a Phase 4 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.
Interventions
- DRUG CPX-351
- BEHAVIORAL Outpatient Care Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-28 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988205
The ClinicalTrials.gov registry entry for NCT03988205 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CPX-351 is the first listed.
NCT03988205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03988205 about?
NCT03988205 is a clinical study titled "Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia". This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.
What is the current status of trial NCT03988205?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2019-08-28. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03988205?
The interventions under investigation include: CPX-351 (DRUG), Outpatient Care Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT03988205?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.